RxDoctor Payments Data

Amanda Vivian, DO

Internal Medicine · Milford, MINPI 1174935191

Payments from drug & device makers

$741in general payments, 2019–2025

Across 39 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$226
  • Astellas Pharma US Inc$119
  • Pfizer$116
  • Sanofi-aventis U.S. LLC$65
  • AstraZeneca$63
  • Novo Nordisk$56
  • plus $96 from 5 others

What the payments were for

  • Food & beverage$66690%
  • Education$7510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$741 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$57,988
Medicare patients
211
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$92,537
OzempicSemaglutide76$91,435
MounjaroTirzepatide45$51,386
JanuviaSitagliptin Phosphate36$39,471
JardianceEmpagliflozin22$29,082
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$24,415
MyrbetriqMirabegron39$22,733
XareltoRivaroxaban14$14,953
FarxigaDapagliflozin Propanediol11$13,854
Tresiba Flextouch U-100Insulin Degludec18$11,942
Wixela InhubFluticasone Propion/Salmeterol18$5,160
Levothyroxine Sodium380$4,555
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,176
Atorvastatin Calcium325$3,866
Metoprolol Succinate181$3,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$116$92,53789 claims
Novo NordiskOzempic$56$91,43576 claims
MerckJanuvia$17$39,47136 claims
Boehringer IngelheimJardiance$19$29,08222 claims
Astellas Pharma US IncMyrbetriq$119$22,73339 claims
Johnson & JohnsonXarelto$226$14,95314 claims
AstraZenecaFarxiga$63$13,85411 claims
NovartisEntresto$23$1,77411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Milford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →